...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: $60m PP Question
3
Jan 03, 2018 12:08AM
4
Jan 03, 2018 12:35PM
4
Jan 03, 2018 04:20PM
3
Jan 03, 2018 11:34PM
2
Jan 04, 2018 04:10PM

Welcome ryaul1135.

The key area of interest to me will the who steps up to the plate in the 10 million share PP and at what price. If the price is above $3 USD then there could be a shot at a NASDAQ. However, Don in the past has seen no value in a NASDAQ listing. Why would he unless the objective of the listing was to raise significant non debt capital to fund R & D at Zenith Epi or to fund acquistions for Zenith Capital. 

However, remember some of the history in terms of Don's statements.

  • Two years ago he said they were looking at a reverse takeover of a distressed company that already had a NASDAQ listing.
  • A year later he dismissed the idea of an IPO and specifically said he would not do a TSX listing.
  • This year he says the 10 M PP is a pre IPO placement.

The fact that Don did not not have a POV on if the IPO would be ZEL or ZCC means his statements were just a bone to toss to very frustrated Zenith shareholders so they could be happy for Christmas.

Also, a pre IPO PP is completely meaningless. Post PP the IPO could be in 10 years???

For me the bottom line at Zenith is that I don't believe there is near enough science developed at this stage for an IPO. This does not mean that parts (or all) of ZEN Epi could be bought or partnered out. Zenith and RVX seem to have somewhat unique approaches.

So I'd say in terms of liquidity don't hold your breath. Of course I'd like to be proven wrong.

Don has his hands full for sure and at RVX he needs to deliver quickly.

Toinv

Share
New Message
Please login to post a reply